Inflammatory disease Archives

rheumatoid arthritis sirukumab galapagos johnson johnson JJ abbvie

News and Trends 3 Mar 2016

Why is J&J getting rid of Galapagos’ shares, when Everyone else is Buying?

J&J has sold over 2 million of Galapagos‘ shares, which had been inherited from previous acquisitions, reducing its equity in this Belgian Biotech to below 5%. What’s wrong? Back in May, we talked about how J&J and AbbVie could be entering a fight for Galapagos’ filgotinib, a drug for rheumatoid arthritis (RA) that performed well […]

March 3, 2016 - 2 minutesmins - By Denise Neves Gameiro

redhill biopharma israel gastrointestinal crohns cancer pancreatic rhb 104

News and Trends 3 Mar 2016

This Leading Israeli Biopharma is in Good Shape to fight Crohn’s Disease

RedHill Biopharma (Israel) is in a solid financial position to reap the benefits of several advanced trials in inflammatory gastrointestinal diseases, including Crohn’s. The company just released its financial statements, with some interesting highlights… Based in Tel-Aviv, RedHill is developing small molecule oral drugs for a variety of conditions connected to the gastrointestinal tract. It is listed […]

March 3, 2016 - 3 minutesmins - By Denise Neves Gameiro

enterome pierre belichard microbiome crohns ibd

News and Trends 3 Feb 2016

Meet the CEO of Europe’s Leading Microbiome Biotech

We met Pierre Belichard, the CEO of Enterome, last week to discuss the increasingly famous trend in the Human Microbiome and how this is impacting therapeutics in Crohn’s disease, the understanding of Medical Microbiomics and investment in this field of Biotech. Enterome, established in 2012, is a French biotech that is hot at the moment, […]

February 3, 2016 - 5 minutesmins - By Philip Hemme

clostridium difficile microbiomics seres health therapeutics nestle science crohns ibd uc cdi

News and Trends 12 Jan 2016

Microbiomics and Nestlé: €1.7Bn for New TransAtlantic Drug Development Program

Microbiomics is a hot area for biotech. Now US Seres Therapeutics and Nestlé Health Sciences have signed a massive drug development deal for bowel diseases and C.difficile infections. By correcting the fundamental microbiome dysbiosis that is the root cause of many diseases, Seres Theraputics in Cambridge (US) is creating a profoundly new and important way […]

January 12, 2016 - 3 minutesmins - By Dani Bancroft

embl microbiome janssen eligo enterome jj inra therapeutics crohns

News and Trends 7 Jan 2016

Collaboration is Key to Microbiomics: New Deal with The Janssen Human Microbiome Institute

The Janssen Human Microbiome Institute, the French National Institute for Agricultural Research (INRA) and Johnson & Johnson Innovation AND Takeda are signing up to collaborate with the Paris biotech Enterome to help accelerate Microbiomics research into Crohn’s Disease. The collaboration is based on initial findings by the INRA showing that some commensal (symbiotic) bacteria elicit […]

January 7, 2016 - 3 minutesmins - By Dani Bancroft

Gilead galapagos abbvie filgotinib partner rheumatoid

News and Trends 18 Dec 2015

Finally! Galapagos New Mystery Partner to Replace AbbVie Revealed in €2Bn Deal

At last! We now know the fate of Galapagos Phase III Rheumatoid Arthritis drug after AbbVie‘s shocking abandonment. The Mystery replacement partner has now been revealed as Gilead! Galapagos will receive an upfront payment of €670M from California’s Gilead, consisting of a license fee of €277M and a €393M equity investment in Galapagos. In addition, […]

December 18, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 22 Oct 2015

For when it actually is Lupus: New Autoimmune Crisis Drug reaches Human Trials

ArGEN-X from Ghent (BE) and Breda (NL) has initiated its phase I human trials for Auto-immune diseases such as systemic lupus erythmatosus (SLE) – a rare chronic disease which has had little progress in the last 50 years. Here is the story behind SLE… As a rare disease, Dr. House and his fictional diagnostics team […]

October 22, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 12 Oct 2015

Roche dishes out €509M for a Humanized antibody against Rheumatoid Arthritis

Adheron Therapeutics is a small California (US) biotech which has developed a phase I monoclonal antibody (mAb) therapy for inflammatory diseases such as Rheumatoid Arthritis. Using the mAb humanisation platform licensed from Abzena (a life Sciences group from Cambridge, UK), Adheron Therapeutics will now be acquired by Swiss giant Roche for €509M. Abzena, based in […]

October 12, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 9 Oct 2015

Fixing the ‘Galapagos-AbbVie Disaster’ through a Cystic Fibrosis Therapy

As we reported last Monday, the AbbVie–Galapagos relationship has proven to be rather rocky as of late, with dramatic action down the NASDAQ Stock exchange. After AbbVie pulled out of the Galapagos Rheumatoid Arthritis pipeline, recent success with their joint-research in Cystic Fibrosis (CF) may kick-start the healing process. Their transport protein potentiator therapy for […]

October 9, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 9 Oct 2015

Biotech of the week: Enterome, the Leading French Microbiome Start-up

This week we’ve left the sunny Portuguese coast behind us and arrived in the ‘City of Lights’, Paris. The capital city of France is famous for the Eiffel Tower, fashion and cuisine but what you may not know it is home to Enterome Bioscience, a pioneer in personalized therapies that focus on microbiome related diseases. […]

October 9, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 2 Oct 2015

Biotech of the week: Cell2b, the Promising Portuguese Cell Therapy Biotech

As it’s a new month, we thought we would try something a little different on Labiotech.eu. Every week we are going to showcase a company of our choice found on our map. The goal is to keep everybody up to date on all the various biotech and pharma companies that are found throughout Europe. This week […]

October 2, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 4 Sep 2015

Gut bacteria growth time can cause disease?

A method of profiling bacterial growth time in the gut’s microbiome has been shown to be a rudimentary diagnostic tool for IBS and diabetes type II. A research team came together from the labs of Dr Elinav and Professor Segal to investigate at the Weizmann Institute of Science, Israel. The millions of bacteria living within our […]

September 4, 2015 - 3 minutesmins - By Dani Bancroft

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Inflammatory disease

Why is J&J getting rid of Galapagos’ shares, when Everyone else is Buying?

This Leading Israeli Biopharma is in Good Shape to fight Crohn’s Disease

Meet the CEO of Europe’s Leading Microbiome Biotech

Microbiomics and Nestlé: €1.7Bn for New TransAtlantic Drug Development Program

Collaboration is Key to Microbiomics: New Deal with The Janssen Human Microbiome Institute

Finally! Galapagos New Mystery Partner to Replace AbbVie Revealed in €2Bn Deal

For when it actually is Lupus: New Autoimmune Crisis Drug reaches Human Trials

Roche dishes out €509M for a Humanized antibody against Rheumatoid Arthritis

Fixing the ‘Galapagos-AbbVie Disaster’ through a Cystic Fibrosis Therapy

Biotech of the week: Enterome, the Leading French Microbiome Start-up

Biotech of the week: Cell2b, the Promising Portuguese Cell Therapy Biotech

Gut bacteria growth time can cause disease?

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!